Introduction
Global Blood Therapeutics (GBT) has been on my radar since late 2017. My first article primarily detailed some risks involved with the company. Subsequent articles (from January 2018 on) became increasingly optimistic as I realized the potential in its, then, investigational drug, voxelotor. To the chagrin of many doubtful bears, the FDA approved the drug on an accelerated basis. Furthermore, the story continues to get better as the FDA requires only a favorably designed confirmatory study for full approval and their drug is off to a solid start in the market.